- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S9682
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other AhR Products | Stemregenin 1 (SR1) BAY 2416964 CH-223191 BAY-218 Tapinarof GNF351 L-Kynurenine YL-109 Diosmin PDM2 |
|
In vitro |
DMSO
: 57 mg/mL
(200.48 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 284.31 | Formula | C19H12N2O |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 172922-91-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | 6-Formylindolo[3,2-b]carbazole | Smiles | O=CC1=C2C(=CC3=C1[NH]C4=C3C=CC=C4)[NH]C5=C2C=CC=C5 | ||
| Targets/IC50/Ki |
AhR
|
|---|---|
| In vitro |
In vitro studies in cells show that CYP1 inhibition in the presence of FICZ results in enhanced AHR activation, suggesting that this compound accumulates in the cell when its metabolism is blocked. It significantly upregulates the gene expression of filaggrin in both HaCaT cells and NHEKs in an AHR-dependent manner, but does not affect the gene expression of other barrier-related proteins. |
| In vivo |
FICZ improves the atopic dermatitis-like skin inflammation, clinical scores, and transepidermal water loss in NC/Nga mice compared with those of control mice. On histology, this compound significantly reduces the epidermal and dermal thickness as well as the number of mast cells. Topical application also significantly reduces the gene expression of Il22. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.